Drugs / S-1
S-1
Trials 344 · started per year
today
2
1
1
3
8
8
9
14
9
10
17
14
17
15
23
16
14
17
21
13
17
13
20
23
23
16
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07356466 | May 2025 → Apr 2027 expected | gastric cancer | Fujian Medical University | Enrolling by invitation | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT06229496 | Aug 2023 → Dec 2027 expected | pancreatic adenocarcinoma | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT03977220 | Jan 2020 → Dec 2021 | gastric cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03380689 | Jan → Jul 2018 | colorectal cancer | Fujian Cancer Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03276156 | Feb 2016 → Feb 2018 | gastric cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02359058 | Feb 2015 → Jul 2016 | gastric neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02347904 | Dec 2014 → Nov 2019 | esophageal cancer | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1 | NCT02277158 | Nov 2014 → Jun 2015 | rectal cancer | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT02387138 | Apr 2014 → Jun 2018 | digestive system cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1 | NCT01946646 | Oct 2013 → Jan 2017 | malignant pancreatic neoplasm | National Taiwan University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01610479 | Jun 2012 → Feb 2017 | cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01693445 | Jun 2012 → Feb 2014 | digestive system neoplasm | Hallym University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01713387 | Apr 2012 → Apr 2015 | biliary tract cancer | Kansai Hepatobiliary Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01291615 | Dec 2010 → Oct 2012 | biliary tract cancer | Kansai Hepatobiliary Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01291407 | Nov 2010 → Aug 2013 | gastric cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01175447 | Feb 2010 → Dec 2011 | esophageal cancer | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01175460 | Jan 2010 → Jan 2011 | esophageal cancer | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01128998 | Nov 2009 | cancer | National Health Research Institutes, Taiwan | Completed | No outcome recorded |
| Phase 1 | NCT00960349 | Aug 2009 → Jan 2010 | gastric cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00506207 | Sep 2006 → Dec 2009 | colorectal neoplasm, gastric neoplasm | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 1 | NCT00400023 | Sep 2006 → May 2007 | neoplasm | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00398424 | Feb 2006 → Nov 2008 | — | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00398307 | Feb 2006 → Sep 2010 | impaired renal function disease | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/225 trials | ||||||
| Phase 1/2 | NCT06732856 | Apr 2025 → Dec 2027 expected | gastric cancer | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06266871 | Mar 2024 → Jun 2026 overdue | gastric cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06038461 | Sep 2023 → Sep 2026 overdue | neuroendocrine neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05403242 | Sep 2022 → Sep 2025 overdue | gastroesophageal adenocarcinoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05322577 | May 2022 → Nov 2025 overdue | gastric cancer, gastroesophageal junction adenocarcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05218889 | Aug 2021 → Dec 2024 overdue | pancreatic ductal adenocarcinoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04662112 | Jun 2021 → Oct 2023 | pancreatic ductal adenocarcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04781413 | Mar 2021 → Mar 2024 | gastric carcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03991104 | May 2019 → Dec 2021 | esophageal cancer | Zhejiang Provincial People's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03654612 | Oct 2018 → Mar 2020 | head and neck cancer | China International Medical Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02995850 | Feb 2017 → Apr 2022 | gastric cancer | Yonsei University | Completed | No outcome recorded |
| Phase 1/2 | NCT03427684 | May → Dec 2016 | gastric cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02564367 | Oct 2015 → Mar 2019 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AIO-Studien-gGmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT01781520 | Jun 2013 → May 2016 | malignant pancreatic neoplasm | Capital Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT01415713 | Mar 2012 → Apr 2016 | pancreatic ductal adenocarcinoma | National Health Research Institutes, Taiwan | Completed | No outcome recorded |
| Phase 1/2 | NCT01542294 | Jun 2011 → Sep 2014 | gastric cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01284413 | Dec 2010 → Aug 2012 | biliary tract cancer | Kansai Hepatobiliary Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01227239 | Sep 2010 → Aug 2013 | rectal carcinoma | Japan Clinical Cancer Research Organization | Unknown | No outcome recorded |
| Phase 1/2 | NCT01110941 | Sep 2009 → Mar 2010 | colorectal cancer | Shen Lin | Completed | No outcome recorded |
| Phase 1/2 | NCT01106066 | Mar 2009 → Nov 2012 | — | Samsung Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00524706 | Aug 2007 → Apr 2011 | colorectal cancer | Shizuoka Cancer Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT00209677 | Dec 2004 → Dec 2007 | malignant pancreatic neoplasm | Hokkaido Gastrointestinal Cancer Study Group | Suspended | No outcome recorded |
| Phase 1/2 | NCT00980382 | Sep 2004 → Aug 2007 | gastric carcinoma | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 1/2 | NCT00072787 | Oct 2003 → Mar 2006 | gastric cancer | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00209638 | May 2000 → Apr 2003 | gastric cancer | Hokkaido Gastrointestinal Cancer Study Group | Completed | No outcome recorded |
| Phase 2237 trials · 2 met primary · 5 missed | ||||||
| Phase 2 | NCT07847710 | Sep 2026 → Mar 2028 expected | intrahepatic cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07602140 | Aug 2026 → Aug 2028 expected | gastric cancer | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07621484 | Jul 2026 → May 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07685704 | Jul 2026 → Jun 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Zhifeng Zhao, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07636824 | Jun 2026 → Feb 2029 expected | carcinoma of gallbladder and extrahepatic biliary tract | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07776639 | May 2026 → Sep 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Yongxu Jia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07000253 | Apr 2026 → Nov 2031 expected | carcinoma of esophagus, gastric adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 2 | NCT07561775 | Apr 2026 → Jan 2028 expected | cholangiocarcinoma | Xingjun Guo | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07515625 | Apr 2026 → Apr 2028 expected | gastric cancer, gastroesophageal adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07507916 | Apr 2026 → Dec 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Show all 237 trials opens the full record — a long page | ||||||
| Phase 2/38 trials · 2 met primary · 1 missed | ||||||
| Phase 2/3 | NCT03691454 | Jun 2018 → Sep 2026 overdue | gastric adenocarcinoma | Peking University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02979691 | Oct 2016 → Apr 2020 | esophageal squamous cell carcinoma, gastroesophageal cancer | Chinese Academy of Medical Sciences | Completed | Met primary |
| Phase 2/3 | NCT02193594 | Jan 2014 → Sep 2017 | gastroesophageal junction adenocarcinoma | Peking University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01704690 | Aug 2012 → Mar 2017 | esophageal cancer | Peking University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01516944 | Feb 2012 → Apr 2018 | gastric cancer | Hebei Medical University | Completed | Met primary |
| Phase 2/3 | NCT02442362 | Jan 2012 → Jan 2014 | gastric cancer | The First People's Hospital of Changzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT00639327 | Mar 2008 → Apr 2011 | gastric cancer | Japan Clinical Cancer Research Organization | Completed | Missed primary |
| Phase 2/3 | NCT00503321 | Oct 2006 → Aug 2009 | gastric cancer | Eastern Network of Cancer Immunological Therapy, Japan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 335 trials · 9 met primary · 4 missed | ||||||
| Phase 3 | NCT07689539 | Sep 2026 → Jul 2028 expected | malignant pancreatic neoplasm | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07366528 | Dec 2025 → Oct 2028 expected | gastric cancer | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06571461 | Sep 2024 → Jan 2028 expected | malignant pancreatic neoplasm | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05771480 | Aug 2023 → Oct 2025 overdue | biliary tract cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04483076 | Jan 2021 → Dec 2022 overdue | gastric cancer | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03941561 | Jan 2019 → Jan 2022 overdue | gastric cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT03708536 | Nov 2018 → Nov 2021 | colorectal adenocarcinoma | Fujian Cancer Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03700333 | Oct 2018 → Oct 2019 | non-small cell lung carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03680261 | Oct 2018 → Sep 2023 | gastric cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02813967 | Jun 2016 → Aug 2020 | esophageal squamous cell carcinoma | Zhejiang Cancer Hospital | Completed | Met primary |
| Phase 3 | NCT02736552 | Mar 2016 → Mar 2019 | gastric cancer | Fudan University | Withdrawn | No outcome recorded |
| Phase 3 | NCT02677597 | Jan 2016 → Jan 2019 | esophageal squamous cell carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT02512380 | Jul 2015 → Jul 2019 | gastric adenocarcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02648841 | Jul 2015 → Jun 2020 | gastric cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02338518 | Jan 2015 → May 2019 | gastric cancer | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 3 | NCT02319187 | Dec 2014 → Dec 2016 | neoplasm of esophagus | Chinese Academy of Medical Sciences | Unknown | Met primary |
| Phase 3 | NCT02182778 | Jul 2014 → Feb 2016 | biliary tract cancer | Kansai Hepatobiliary Oncology Group | Completed | Met primary |
| Phase 3 | NCT02114359 | Feb 2014 → Feb 2020 | gastric cancer | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03061058 | Apr 2013 → Dec 2018 | chemotherapy-induced toxicity, gastric neoplasm | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT01824459 | Apr 2013 → Dec 2018 | gastric cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT01583361 | Mar 2012 → Sep 2014 | gastric adenocarcinoma | Lin Chen | Unknown | No outcome recorded |
| Phase 3 | NCT01534546 | Mar 2012 → Jul 2019 | gastric adenocarcinoma | Peking University | Unknown | Met primary |
| Phase 3 | NCT01515748 | Dec 2011 → Jan 2019 | gastric cancer | Sanofi | Completed | Met primary |
| Phase 3 | NCT01795027 | Sep 2011 → Nov 2016 | gastric cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01285557 | Apr 2011 → Aug 2014 | diffuse gastric cancer | Taiho Oncology, Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00869635 | Feb 2009 → Jul 2013 | cholangiocarcinoma | Asan Medical Center | Completed | Met primary |
| Phase 3 | NCT00770874 | Sep 2008 → Dec 2015 | cervical cancer | Taiho Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 3 | NCT01198392 | Sep 2008 → Dec 2011 | gastric cancer | Sun Yat-sen University | Unknown | Missed primary |
| Phase 3 | NCT00677443 | Jun 2008 → Sep 2009 | colorectal cancer | Samsung Medical Center | Completed | Met primary |
| Phase 3 | NCT00602745 | Feb 2008 → Mar 2010 | malignant pancreatic neoplasm, metastatic malignant neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00287768 | Mar 2006 → Sep 2008 | gastric cancer | Japan Clinical Cancer Research Organization | Completed | Met primary |
| Phase 3 | NCT00202969 | Jul 2005 → Jan 2007 | gastric cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00400179 | May 2005 → Mar 2008 | gastric cancer | Taiho Oncology, Inc. | Completed | Missed primary |
| Phase 3 | NCT00152217 | Sep 2001 → May 2007 | gastric cancer | Taiho Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT00142350 | Nov 2000 → Jan 2007 | gastric cancer | Japan Clinical Oncology Group | Completed | Mixed |
| Phase 44 trials | ||||||
| Phase 4 | NCT06779318 | Jul 2025 → Jul 2027 expected | malignant pancreatic neoplasm | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04217096 | Jan 2020 → Sep 2022 | pancreatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 4 | NCT01997957 | Oct 2013 → Sep 2016 | hepatocellular carcinoma | Zhu Xu | Unknown | No outcome recorded |
| Phase 4 | NCT01849380 | Jun → Oct 2013 | breast cancer | Shandong University | Unknown | No outcome recorded |
| Phase not applicable12 trials · 1 met primary | ||||||
| — | NCT07855757 | Jun 2026 → Jun 2028 expected | gastric cancer, peritoneal carcinomatosis | Zhejiang Cancer Hospital | Active not recruiting | No outcome recorded |
| — | NCT06966440 | Jun 2025 → Jun 2028 expected | pancreatic adenocarcinoma | Ruijin Hospital | Recruiting | No outcome recorded |
| — | NCT06171321 | Dec 2023 → Nov 2025 | biliary tract cancer | Shanghai East Hospital | Unknown | No outcome recorded |
| — | NCT04889768 | Jul 2021 → Jul 2023 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04886193 | Apr 2021 → May 2022 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04274270 | Apr 2020 → Jan 2022 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT05028439 | Jan 2020 → Dec 2022 | cholangiocarcinoma | First People's Hospital of Hangzhou | Completed | No outcome recorded |
| — | NCT04047953 | Sep 2019 → Dec 2023 overdue | gastric adenocarcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| — | NCT03413514 | Jan 2018 → Jan 2019 | gastric cancer | Peking University | Unknown | No outcome recorded |
| — | NCT02592538 | Dec 2015 → Aug 2018 | cholangiocarcinoma | First People's Hospital of Hangzhou | Completed | No outcome recorded |
| — | NCT02981641 | Dec 2015 → Dec 2016 | pancreatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01364376 | Jun 2011 → Aug 2016 | gastric neoplasm | Zhejiang University | Completed | Met primary |
| Comparator or background therapy111 trials | ||||||
| Phase 1 | NCT05867121 Background | Oct 2023 → Mar 2026 | gastric cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03162510 Background | Jun 2018 → Jun 2021 | biliary tract cancer, malignant pancreatic neoplasm, stomach carcinoma in situ | National Health Research Institutes, Taiwan | Completed | No outcome recorded |
| Phase 1 | NCT02862535 Background | Sep 2016 → Oct 2019 | gastric adenocarcinoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT00553696 Background | Nov 2007 → Jul 2009 | gastric neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479076 Background | Mar 2007 → Jan 2011 | neoplasm | Sanofi | Completed | No outcome recorded |
| Show all 111 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-04-10 | InnoPharmax Inc. | Results Completion of Stage 1 in the Phase II/III Clinical Trial of D07001 Softgel Capsules for Advanced Biliary Tract Cancer. innopharmax.com ↗
Data indicate that D07001 softgel capsules, at the maximum tolerated dose (MTD), can be safely combined with Xeloda or TS-1, supporting dose selection for subsequent studies. |
| 2016-12-13 | TTY Biopharm | Regulatory 台灣東洋藥品公司之癌症口服化療藥物獲胃癌術後輔助性治療之健保給付 [財經版] com.tw ↗
這是此癌症口服化療藥物繼2014年6月取得『局部晚期無法手術切除或轉移性胰臟癌病人』給付後，第二個獲健保給付的適應症。 |
| 2014-06-01 | TTY Biopharm | Regulatory 台灣東洋癌症用藥TS-1(愛斯萬® )獲晚期胰臟癌之健保給付 com.tw ↗
現台灣通過晚期胰臟癌健保給付，將提供病人一個有效且方便性高的新治療選擇，每年可嘉惠約1,500位晚期胰臟癌患者。 |
| 2007-07-23 | Jeil Pharmaceutical Co., Ltd. | Results 항암제 "TS-1" 위암 사망 32% 감소 jeilpharm.co.kr ↗
그 결과, TS-1 투여그룹의 사망위험은 비투여 그룹에 비해 32% 감소했으며, 3년 후 생존율은 비투여 그룹이 70.1%, 투여그룹이 80.5%를 나타냈다. |
| 2007-07-23 | Jeil Pharmaceutical Co., Ltd. | Results TS-1에 시스플라틴 병용 생존기간 연장 jeilpharm.co.kr ↗
그 결과, 병용그룹은 단독그룹에 비해 사망위험이 22.6% 유의하게 감소한 것으로 나타났다. |
| 2002-10-28 | Jeil Pharmaceutical Co., Ltd. | Results 경구용 항암제 TS-1 심포지엄 jeilpharm.co.kr ↗
또한, TS-1과 Cisplatin 병용요법 2상 결과에서 76%의 경이적인 유효율을 나타냈다는 점에 놀라움을 표시하며, 본 약제가 보다 빨리 국내에 도입되어 많은 암환자에게 새로운 희망을 줄 수 있기를 기대했다. |
All press releases naming this drug 11 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 457 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-1 | “Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1...” NCT06966440 ↗458“S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an...” NCT04267549 ↗ “In this open-label, single-arm, phase 2 trial, in each 21-day cycle, eligible patients received 200 mg intravenous camrelizumab in the first day, 500 mg oral apatinib once...” PMID 35304622 ↗ Mar 2022 “SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25...” NCT06121700 ↗ “Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or...” NCT01781520 ↗ “Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine...” NCT03680261 ↗ “A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin...” PMID 32583567 ↗ Jun 2020 “Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid...” NCT02870153 ↗ “SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid,...” NCT02356276 ↗ “Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130...” NCT05975749 ↗ “S-1 is orally administer by BSA (\<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses a day after breakfast and dinner for 14 days every three weeks...” NCT03961867 ↗ |
| Known as | 452500ACH | “S-1 (452500ACH)” NCT02191566 ↗ |
| Known as | S-1 (TS-1, Taiho, JP) | “S-1 (TS-1, Taiho, JP)” NCT04999332 ↗ |
| Known as | S-1; TS-1 | “S-1; TS-1” NCT01096745 ↗ |
| Known as | S1: Gimeracil and oteracil porassium capsules | “S1: Gimeracil and oteracil porassium capsules” NCT02223611 ↗ |
| Known as | Tegafur Gimeracil Oteracil Potassium | “S-1 (tegafur-gimeracil-oteracil potassium) combined with radiotherapy in these subsets of ESCC patients” PMID 35449578 ↗ Apr 20222“Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)” NCT00503321 ↗ “Tegafur Gimeracil Oteracil Potassium Capsules (S-1)” NCT07304258 ↗ |
| Known as | Tegafur, Gimeracil and Oteracil Porassium Capsules | “Drug: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)” NCT03475615 ↗ |
| Known as | Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) | “A Phase I Study of Concurrent Radiotherapy and Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.” NCT02277158 ↗ |
| Known as | Tegafur/Gimeracil/Oteracil | “The SOX regimen consisted of three cycles of oxaliplatin 130 mg/m2 intravenous on day 1 and oral Tegafur/Gimeracil/Oteracil (S-1) 80 mg/m2 twice daily on days 1-14, repeated...” PMID 41181842 ↗ Oct 2025 |
| Known as | Teysuno | “Postoperative ctDNA-negative patients receive oral Teysuno (S-1) for adjuvant therapy。” NCT06171321 ↗ |
| Known as | Tiggio capsule | “Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;” NCT04886193 ↗ |
| Known as | Tiggio Capsules | “Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w” NCT05193292 ↗ |
| Known as | Tigio | “Tigio (S-1), 40-60 mg orally twice daily on days 1 to 14.” NCT06576921 ↗ |
| Known as | Tigio Capsules | “Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.” NCT04792515 ↗ |
| Known as | TS-1 | “Tegafur / gimeracil / oteracil potassium (TS-1) is widely used as a first-line drug for unresectable advanced gastric carcinoma and recurrent gastric carcinoma in Japan” NCT00503321 ↗4“Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.” PMID 19052037 ↗ Dec 2008 “S-1 (TS-1) and Oxaliplatin (Oxalitin)” NCT00961077 ↗ “Gemcitabine;gemzer , S-1;TS-1” NCT01713387 ↗ “TS-1 (S-1)” NCT00152217 ↗ |
| Action | Inhibit | “inhibit dihydropyrimidine dehydrogenase (DPD)” NCT00072787 ↗ |
| Modality | Small molecule | “S-1 is an oral fluoropyrimidine” NCT00072787 ↗ |
| Route | Oral | “S-1 is an oral fluoropyrimidine” NCT00072787 ↗ |